DAWN Profile
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for genetically defined cancers. The company is dedicated to addressing unmet medical needs in oncology through innovative drug development. Its lead product candidate, DAY101, is an oral, brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase (RAF) inhibitor. DAY101 is currently undergoing Phase II clinical trials aimed at evaluating its efficacy and safety in pediatric patients with relapsed or progressive low-grade glioma, a type of brain tumor.
In addition to DAY101, Day One Biopharmaceuticals is advancing Pimasertib, an oral small molecule inhibitor targeting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). Pimasertib is designed to inhibit key signaling pathways involved in tumor growth and progression, and is being developed for various oncology indications. The company’s pipeline reflects a strategic focus on therapies that offer precision treatment options based on genetic and molecular profiles of cancers.
Founded in 2018, Day One Biopharmaceuticals has quickly positioned itself at the forefront of cancer drug development by prioritizing treatments for rare and challenging cancers with high unmet needs. The company's approach integrates advanced scientific research with a commitment to delivering novel therapies that can significantly impact patient outcomes.
Headquartered in South San Francisco, California, Day One Biopharmaceuticals benefits from its proximity to a major biotech hub, fostering collaboration with leading researchers and leveraging the region’s innovation ecosystem. The company’s strategic location supports its mission to advance cutting-edge cancer therapies and contribute to the advancement of precision medicine in oncology.
|
